Atle Fund Management AB reported 39 positions worth $371.70M for the quarter ended Jun 30, 2026, up 26.7% on the prior quarter. It opened 6 new positions, added to 16, trimmed 17 and exited 2. Its largest holding is ELI LILLY & Co at 9.6% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| MRK Merck & Co., Inc. | +155.5K | +459.4% | $19.98M | 6.55% |
| RVMD Revolution Medicines, Inc. | +73.1K | – | $13.69M | 3.68% |
| BIIB Biogen Inc. | +62.8K | – | $13.56M | 3.65% |
| CVS CVS HEALTH Corp | +122.3K | +514.6% | $12.65M | 4.07% |
| IONS Ionis Pharmaceuticals Inc | +109.3K | +392.0% | $8.66M | 2.93% |
| TNGX Tango Therapeutics, Inc. | +168.6K | +563.7% | $5.27M | 1.67% |
| ORKA Oruka Therapeutics, Inc. | +54.9K | – | $5.22M | 1.41% |
| NAMS NewAmsterdam Pharma Co N.V. | +154.1K | +162.5% | $5.22M | 2.27% |
| DXCM Dexcom Inc | +71.8K | – | $4.84M | 1.3% |
| BSX Boston Scientific Corp | +105.9K | +262.0% | $4.52M | 1.68% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| CAH Cardinal Health Inc | -85.1K | -78.3% | $20.20M | 1.51% |
| ISRG Intuitive Surgical Inc | -46.2K | -65.2% | $18.37M | 2.64% |
| LLY ELI LILLY & Co | -9,901 | -24.9% | $11.88M | 9.62% |
| CELC Celcuity Inc. | -108.0K | -76.4% | $11.30M | 0.938% |
| MIRM Mirum Pharmaceuticals, Inc. | -95.0K | -48.5% | $11.12M | 3.17% |
| ABBV AbbVie Inc. | -43.9K | -40.5% | $11.04M | 4.35% |
| AMGN Amgen Inc | -21.9K | -100.0% | $8.72M | Exited |
| KRYS Krystal Biotech, Inc. | -13.6K | -36.1% | $5.04M | 2.4% |
| IRON Disc Medicine, Inc. | -63.6K | -59.3% | $4.65M | 0.86% |
| INSM INSMED Inc | -39.1K | -40.1% | $4.16M | 1.67% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| RVMD Revolution Medicines, Inc. | +73.1K | $13.69M | 3.68% |
| BIIB Biogen Inc. | +62.8K | $13.56M | 3.65% |
| ORKA Oruka Therapeutics, Inc. | +54.9K | $5.22M | 1.41% |
| DXCM Dexcom Inc | +71.8K | $4.84M | 1.3% |
| BCAX Bicara Therapeutics Inc. | +145.7K | $4.32M | 1.16% |
| JBIO Jade Biosciences, Inc. | +88.6K | $1.97M | 0.529% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | LLY ELI LILLY & Co | Healthcare | 29.8K | $35.77M | 9.62% | -9,901 | -24.9% | Reduced | 0% |
| 2 | MRK Merck & Co., Inc. | Healthcare | 189.4K | $24.33M | 6.55% | +155.5K | +459.4% | Added | 0.01% |
| 3 | JNJ Johnson & Johnson | Healthcare | 85.4K | $21.70M | 5.84% | -6,952 | -7.5% | Reduced | 0% |
| 4 | ABBV AbbVie Inc. | Healthcare | 64.3K | $16.19M | 4.35% | -43.9K | -40.5% | Reduced | 0% |
| 5 | CVS CVS HEALTH Corp | Healthcare | 146.1K | $15.11M | 4.07% | +122.3K | +514.6% | Added | 0.01% |
| 6 | TMO Thermo Fisher Scientific Inc. | Healthcare | 27.9K | $13.97M | 3.76% | +4,873 | +21.2% | Added | 0.01% |
| 7 | RVMD Revolution Medicines, Inc. | Healthcare | 73.1K | $13.69M | 3.68% | +73.1K | – | New | 0.03% |
| 8 | BIIB Biogen Inc. | Healthcare | 62.8K | $13.56M | 3.65% | +62.8K | – | New | 0.04% |
| 9 | NBIX Neurocrine Biosciences Inc | Healthcare | 72.9K | $12.29M | 3.31% | -16.8K | -18.7% | Reduced | 0.07% |
| 10 | MIRM Mirum Pharmaceuticals, Inc. | Healthcare | 100.8K | $11.80M | 3.17% | -95.0K | -48.5% | Reduced | 0.16% |
| 11 | ALKS Alkermes plc. | Healthcare | 213.3K | $11.18M | 3.01% | -29.1K | -12.0% | Reduced | 0.13% |
| 12 | IONS Ionis Pharmaceuticals Inc | Healthcare | 137.1K | $10.87M | 2.93% | +109.3K | +392.0% | Added | 0.08% |
| 13 | ONC BeOne Medicines Ltd. | Healthcare | 35.2K | $10.03M | 2.7% | -6,537 | -15.7% | Reduced | 0.03% |
| 14 | ISRG Intuitive Surgical Inc | Healthcare | 24.7K | $9.81M | 2.64% | -46.2K | -65.2% | Reduced | 0.01% |
| 15 | SYK Stryker Corp | Healthcare | 30.3K | $9.53M | 2.57% | +3,448 | +12.8% | Added | 0.01% |
Tip. Select a row to see that position’s full history at Atle Fund Management AB.
As of its Q2 2026 13F filing, Atle Fund Management AB’s five largest positions were ELI LILLY & Co (LLY) at 9.6%, Merck & Co., Inc. (MRK) at 6.5%, Johnson & Johnson (JNJ) at 5.8%, AbbVie Inc. (ABBV) at 4.4%, CVS HEALTH Corp (CVS) at 4.1% of the reported portfolio.
Atle Fund Management AB reported a 13F portfolio worth $371.70M across 39 positions for Q2 2026. That is up 26.7% from the previous quarter.
Its largest purchases by value were Merck & Co., Inc. ($19.98M), Revolution Medicines, Inc. ($13.69M), Biogen Inc. ($13.56M). It opened 6 new positions.
Its largest sales by value were Cardinal Health Inc ($20.20M), Intuitive Surgical Inc ($18.37M), ELI LILLY & Co ($11.88M). It exited 2 positions entirely.
From the Form 13F-HR reports Atle Fund Management AB files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.